asa glp 1 agonists Perioperative management of patients taking glucagon-like peptide receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement asa guidelines for glp 1
Description
The cardiovascular benefits appear to precede any significant weight management and apply to people with or without type 2 diabetes
doi: 10.7573/dic.212283
The FDA is expected to issue its decision by no later than March 2026
D.QuerciF.et al (2010a)
GLP-1 receptor agonists (GLP-1 RAs), already established in the management of type 2 diabetes mellitus and obesity, have emerged as promising candidates for the treatment of nonalcoholic steatohepatitis (NASH), owing to their broad metabolic and hepatoprotective effects
